1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Deals

Perrigo Pays For Growth Drivers In Q1 Results

 
• By Malcolm Spicer

Perrigo reports $1.2bn net sales, up 13% excluding loss to foreign exchange or 6.4% on an organic measure excluding additions to its portfolio and other operating changes since the year-ago period, but also a $3m net loss.

• Source: Shutterstock

Perrigo Company PLC reported 10% net sales growth in the first quarter, driven by a nearly 15% increase in its international markets, but its net loss for the period grew $600,000 from a year ago to $3m on costs related to paying for businesses and brands driving its growth.

One of those businesses, HRA Pharma, is presenting its case for approval of the first US OTC daily oral contraceptive in a two-day meeting of a Food and Drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Haleon Utilizing AI To Develop Natural CHC Products

 
• By Tom Gallen

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

Astaxanthin Specialist AstaReal Diversifies With Garlic Supplement For Heart Health

 
• By Tom Gallen

Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.

Italy’s PharmaNutra Grows Presence In Americas And MENA

 
• By Tom Gallen

Iron supplements specialist PharmaNutra has penned distribution deals to take its products to additional markets across the Americas and the Middle East & North Africa.

More from Business

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 
• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.